I

ImmunityBio, Inc. Tech Stack

Cell and immunotherapy developer for oncology and infectious diseases

Biotechnology Research San Diego, CA 501–1,000 employees Founded 2014 Public Company

ImmunityBio is a public biotech company developing cell and immunotherapy products focused on activating innate immune responses to attack cancer and infected cells. The hiring mix reflects a manufacturing-intensive operation: healthcare and research roles dominate, followed by significant manufacturing and legal hiring—consistent with their active projects around CMC regulatory strategy, equipment qualification, facility buildouts, and ERP system development. Pain points around cGMP compliance, production shortages, and treatment adoption signal a company scaling from development into commercial manufacturing and market deployment.

Tech Stack 21 technologies

Core StackWorkday BMS Outlook Word PowerPoint Excel EudraVigilance qPCR HPLC Veeva RIM Veeva Vault XML Meta Google YouTube

AdoptingMES

What ImmunityBio, Inc. Is Building

◆Challenges

Compliance with cgmp
Continuous lab operation
Low treatment adoption
Achieving revenue targets in bladder cancer market
Prescriber adoption barriers
Meeting turnaround time requirements
Production shortages
Inventory inefficiencies
Improving lab operations
Global labeling compliance

▲Active Projects

Global cmc regulatory strategy
Equipment qualification and validation
Planning best practices implementation
Anktiva treatment adoption
Preparation of dossiers in ectd format
Instrument installation and operational qualification
Utilities
Incident and disaster planning
Erp system development
Facility buildouts

Hiring Activity

Accelerating90 roles · 50 in 30d

Department

Healthcare

16

Research

12

Manufacturing

11

Legal

10

Ops

7

Sales

7

Engineering

6

HR

6

Seniority

Senior

35

Mid

21

Director

13

Manager

11

Junior

9

Principal

3

Notable leadership hires: Field Medical Director, Sales Training Director, Area Business Director, Clinical Implementation Director, Business Director

Company intelligence

Find more companies like ImmunityBio, Inc. by tech stack, pain points and active projects

Get started free

About ImmunityBio, Inc.

ImmunityBio develops cell and immunotherapy products designed to strengthen patients' natural immune systems against cancer and infectious diseases. Founded in 2014 and based in San Diego, the company operates as a public biotech with 501–1,000 employees. The product pipeline includes approaches to activate both innate and adaptive immunity, with a focus on building immunological memory. Current commercial efforts center on oncology (notably bladder cancer) and infectious disease indications. The company's infrastructure spans clinical development, regulatory affairs (using Veeva RIM and Vault for compliance), manufacturing operations, and commercial sales.

HeadquartersSan Diego, CA

Company Size501–1,000 employees

Founded2014

Hiring MarketsUnited States

Frequently Asked Questions

What is ImmunityBio's technology platform?

ImmunityBio develops cell and immunotherapy products that activate the innate immune system to target cancerous and infected cells while building immunological memory. The approach focuses on strengthening natural immune defenses rather than replacing them.

Where is ImmunityBio headquartered?

ImmunityBio is headquartered in San Diego, California. The company is publicly traded and was founded in 2014.

What are ImmunityBio's main challenges?

Active pain points include cGMP compliance, production shortages, inventory inefficiencies, low treatment adoption rates, and prescriber adoption barriers—particularly in the bladder cancer market. The company is also working to improve lab operational continuity and meet turnaround time requirements.